QR-koodi

Efficacy and Safety of Radioligand Therapy with Actinium-225 DOTATATE in Patients with Advanced, Metastatic or Inoperable Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

<i>Background and Objectives</i>: Peptide receptor radionuclide therapy (PRRT) using radiopharmaceuticals labelled with Lutetium-177 is currently a therapeutic option for patients with advanced neuroendocrine neoplasms overexpressing somatostatin receptors (SSTRs). One promising option that has gain...

Täydet tiedot

Tallennettuna:
Päätekijät: Alessio Rizzo, Alessio Imperiale, Salvatore Annunziata, Roberto C. Delgado Bolton, Domenico Albano, Francesco Fiz, Arnoldo Piccardo, Marco Cuzzocrea, Gaetano Paone, Giorgio Treglia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI AG 2025-07-01
Sarja:Medicina
Aiheet:
neuroendocrine
radioligand therapy
Actinium-225
DOTATATE
alpha-emitting
somatostatin
Linkit:https://www.mdpi.com/1648-9144/61/8/1341
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia